Expanded eligibility for Natera’s Financial Assistance Program
Read Article
Blog
Revolutionizing the standard of care with next-generation, cell-free DNA testing.
-
-
What ASCO GI 2026 Means for Patients: How MRD Research Is Shaping GI Cancer Care
Read Article
-
Meet Jon, Muscle-Invasive Bladder Cancer (MIBC) Survivor and Signatera Patient
Read Article
-
Meet Amanda, Colorectal Cancer Survivor and Signatera Patient
Read Article
-
How to Prepare for Your Next MRD Test: Practical Tips and FAQs
Read Article
-
Looking Back at 2025: How Natera Supported Cancer Survivors
Read Article
-
Understanding the IMvigor011 Study: How Signatera™ Helps Guide Bladder Cancer Treatment
Read Article
-
Facing Recurrence Again? How MRD Testing Can Support You Every Step of the Way
Read Article
-
Navigating Lung Cancer with Confidence: Making the Most of the Natera Patient Portal
Read Article
-
How MRD Testing for Recurrence and IO Therapy Provides Peace of Mind
Read Article
-
Kyle’s Colon Cancer Story
Read Article
-
Why Regular MRD Testing Matters for Ovarian Cancer Patients
Read Article
-
How MRD Testing Supports Ovarian Cancer Patients: Holly’s Story
Read Article
-
Dr. James Duke’s Head & Neck Cancer Story
Read Article
-
Anj’s Breast Cancer Story
Read Article
-
MRD Testing vs. Traditional Cancer Monitoring: What’s the Difference?
Read Article
-
Understanding Hereditary Cancer Risks in Ovarian Cancer
Read Article
-
How MRD Testing Helps Monitor Ovarian Cancer Recurrence
Read Article
-
A Rare Cancer, A Powerful Tool: What the New Guidelines Mean for Merkel Cell Carcinoma Patients
Read Article
-
How MRD Testing Supports Colorectal Cancer Patients: Jason’s Story and the Importance of Regular Monitoring
Read Article
-
Loading More...
